ArticleQuantitative imaging in medicine and surgery2025
Deep medullary veins: a promising neuroimaging marker for neurodegeneration in multiple sclerosis.
Article in Quantitative imaging in medicine and surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). Recent studies have shown that different forms of vascular abnormalities may be related to the pathogenesis of MS. Susceptibility-weighted imaging (SWI) can directly image intracranial venules. The aim of this study was to investigate the association between deep medullary veins (DMVs) and the degree of neurodegeneration in patients with MS. Methods: In this prospective cross-sectional study, 34 patients with MS and 30 age-matched healthy controls (HCs) were recruited. The count and score of DMVs, which can reflect the visibility and continuity of DMVs were evaluated based on SWI. The differences between the group with a high DMV score (DMV >10) and the group with a low DMV score (DMV ≤10) were assessed. The association of DMV change with neurodegeneration neuroimaging markers [including amount and volume of white matter lesion (WML), degree of cortical atrophy, whole-brain atrophy, and deep gray matter (DGM) atrophy] and clinical Expanded Disability Status Scale (EDSS) were observed in patients with MS. Results: It was found that compared with controls, patients with MS (n=34) had a significantly lower DMV count (P<0.001) and a significantly higher DMV score (P<0.001). The low- and high-DMV score groups differed significantly in terms of EDSS (P=0.048) and neurodegeneration neuroimaging indicators, including WML volume (P=0.015), brain parenchymal fraction (BPF) (P=0.047), thalamic fraction (P=0.036), and caudate fraction (P=0.015). In the correlation analysis of the MS group, DMV count was negatively correlated with the number of WMLs (r=-0.535; P=0.001) and the WML volume (r=-0.416; P=0.014) but positively correlated with the neuroimaging measurements reflecting the degree of whole-brain atrophy and DGM atrophy. Furthermore, the DMV score was positively correlated with EDSS (r=0.450; P=0.008), number of WMLs (r=0.490; P=0.003), and WML volumes (r=0.635; P=0.001) but negatively correlated with the neuroimaging measurements reflecting the degree of whole-brain atrophy and DGM atrophy. Conclusions: Reduced DMV visibility and continuity could reflect the severity of neurodegeneration in patients with MS. DMV count and score may be imaging indicators for assessing the severity of MS.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.